- Home
- GERN vs QURE Comparison
GERN vs QURE Comparison
Compare GERN & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | QURE |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | Netherlands |
| Employees | 229 | 248 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | GERN | QURE |
|---|---|---|
| Price | $1.47 | $24.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $2.17 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 14.8M | 1.6M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $26.91 | $126.12 |
| Revenue Next Year | $43.75 | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.04 | $8.73 |
| 52 Week High | $2.01 | $71.50 |
Technical Indicators
Market Signals| Indicator | GERN | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 71.40 |
| Support Level | $1.44 | $22.59 |
| Resistance Level | $1.49 | $25.66 |
| Average True Range (ATR) | 0.09 | 1.53 |
| MACD | -0.00 | 0.66 |
| Stochastic Oscillator | 16.13 | 98.10 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.